Accession Number:

AD1095326

Title:

Cancer-Associated Macrophagelike (CAML) Cells to Enhance Detection of Early-Stage Lung Cancer and Relapse After Definitive Treatment

Descriptive Note:

Technical Report,15 Jul 2018,14 Jul 2019

Corporate Author:

Creatv MicroTech, Inc. Potomac United States

Personal Author(s):

Report Date:

2019-08-01

Pagination or Media Count:

9.0

Abstract:

Lung cancer is the number one cause of cancer death in the United States. Low dose CT LDCT was recommended to screen for lung cancerfor smokers by the US Preventative Services Task Force. However, there are several problems with the current screening paradigm. Mostcritically, over 39 of screened subjects were determined to have positive screens with 96.4 false positive. This very high false positive rateresults in several critical problems including the requirement for further testing scans, biopsies, the potential of loss to follow-up, thepossibility of false negative biopsy and the resultant patient stress and anxiety. While lung nodules 0.8 cm are considered low-risk findingsand nodules 3.0 cm high-risk, nodules between from 0.8-3.0 cm have been described as indeterminate and represent a managementchallenge. Therefore, there is a substantial need for a method to enrich the population of patients identified as likely to have malignancy andexclude those who have nodules not likely to have malignancy.

Subject Categories:

  • Medicine and Medical Research
  • Anatomy and Physiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE